Tracer study for kidney transplant monitoring
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at a new blood test to help monitor the health of your transplanted kidney and check for early signs of rejection. The test will be done as part of your usual care after a kidney transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have had a kidney transplant (from a living or deceased donor, first or repeat).
- You must be at least 1 month past your kidney transplant.
- You must be on anti-rejection medication as prescribed by your transplant team.
- Your doctor must have decided you will have the TRAC blood test as part of your normal care.
- You must not have had a previous transplant of a non-kidney organ (like a heart, liver, or pancreas) or islet cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new blood test (called TreaT-Assay) to help diagnose acute rejection after a kidney transplant. The goal is to catch rejection earlier and more accurately, so you can get the right treatment faster.
This study is creating a registry to learn how the immune system responds to BK virus in people who have recently received a kidney transplant from a deceased donor. Researchers hope this information will help improve treatment for BK virus infections.
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
This study tests whether a special blood test can help monitor your new kidney after transplant. It may help doctors spot problems earlier and improve kidney health.
This trial uses a virus called TTV to see if it can help doctors safely adjust immunosuppression drugs in kidney transplant patients. It aims to find a way to lower the risk of rejection while reducing side effects.
This study follows people who are getting a kidney transplant (first or later) to better understand how the body recovers, using health tracking and “gene/protein” (proteogenomic) information. It may help doctors predict complications and improve care after transplant.
Hear when a new Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.